PWA
BCRX icon

Physician Wealth Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Physician Wealth Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-80
Closed -$717 – 1917
2025
Q2 		$717 Buy
+80
New +$745 ﹤0.01% 1594

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Physician Wealth Advisors's BCRX Position: Q3 2025 in Review

Physician Wealth Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 80 shares — an estimated $717 sold.

Physician Wealth Advisors first reported a position in BCRX in Q2 2025 and held it in 1 quarter. The position peaked at $717 in Q2 2025. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

  • Physician Wealth Advisors reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Physician Wealth Advisors sold 80 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $717.
  • Physician Wealth Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Physician Wealth Advisors's BioCryst Pharmaceuticals position peaked at $717 in Q2 2025.
  • 286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Physician Wealth Advisors's 13F filing for Q3 2025, filed 4 Nov 2025.